AstraZeneca PLC (AZN) on Decifer

Decifer ranks AZN number 185 of 265 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 13% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 9% a year and profits grew 45% over the past year.
• It keeps a high share of every sale as profit, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders and its own insiders have been buying.
• 45 percent profit growth on 9 percent revenue growth is not enough to overcome 4 momentum below trend and no growth reason.

The current read

The evidence on AZN lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full AZN research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.